Current considerations for the effective safety evaluation of drugs in vitro

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 7, 2009, Pages 861-868

  Xu, Jinsheng ^a   Jackson, Simon K ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DINITROBENZENE; ALCOHOL; DICLOFENAC; GALACTOSAMINE; NITRIC OXIDE; PARACETAMOL; PROPRANOLOL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STREPTOMYCIN; VALPROIC ACID;

CELL SPREADING; CELL VIABILITY; COMPUTER MODEL; CONCENTRATION RESPONSE; DNA ADDUCT; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SAFETY; DRUG SCREENING; HEARING LOSS; HUMAN; IN VITRO STUDY; LC 50; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RISK ASSESSMENT; SPHEROID CELL; TOXICITY TESTING; ANIMAL; BIOASSAY; DRUG TOXICITY; METHODOLOGY; QUALITY CONTROL; STANDARD;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; ENDPOINT DETERMINATION; HUMANS; QUALITY CONTROL; REFERENCE STANDARDS; RISK ASSESSMENT;

EID: 68849099326     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788452577     Document Type: Review

References (41)

1. Bugrim, A.; Nikolskaya, T.; Nikolsky, Y. Early prediction of drug metabolism and toxicity: systems biology approach and modelling. Res. Focus. Rev., 2004, 9, 127-135.
2. Aronove, A. M. Predictive in silico modelling for hERG channel blockers. Drug Discov. Today: Biosilico, 2005, 10, 149-155.
3. Baily, A.B.; Chanderbhan, R.; Collazo-Braier, N.; Cheeseman, M.A.; Twaroski, M. L. The use of structure-activity relationship analysis in the food contact notification program. Regul. Toxicol. Pharmacol., 2005, 42, 225-235.
4. Mager, D. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv. Drug Deliv. Rev., 2006, 58, 1326-1356.
5. Lipscomb, J. C.; Poet T. S. In vitro measurement of metabolism for application in pharmacokinetic modelling. Pharmacol. Ther., 2008, 118, 82-103.
6. Raven, P. H.; Johnson, R. Biology, 5th ed. WCB/McGraw-Hill, London, 1999, pp 105-126, 1169-1192.
7. Clamp, M.; Fry, B.; Kamal, M.; Xie, X.; Cuff, J.; Lin, M.F.; Kellis, M.; Lindblad-Toh, K.; Lander, E.S. Distinguishing protein-coding and noncoding genes in the human genome. Proc. Natl. Acad. Sci. USA, 2007, 104, 19428-33.
8. Alexander, B. The role of nitric oxide in hepatic metabolism. Nutrition, 1998, 14, 376-390.
9. Wiesinger, H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Progr. Neurobiol., 2001, 64, 365-391.
10. Jaeschke, H.; Knight, T. R.; Bajt, M. L. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol. Lett., 2003, 144, 279-288.
11. Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
12. Drechsel, D. A.; Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic. Biol. Med., 2008, 44, 1873-1886.
13. Cairo G, Recalcati S, Pietrangelo A. and Minotti, G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic. Biol. Med., 2002, 32, 1237-1243.
14. Gardner, P. R. ; Nguyen, D. D.; White, C. W. Aconitase is a sensitive and critical target of oxygen poisoning in cultured mammalian cells and in rat lungs. Proc. Natl. Acad. Sci. USA, 1994, 91, 12248-12252.
15. Zeevalk, G. D.; Razmpour, R.; Bennard, L. P. Glutathione and parkinson's disease: Is this the elephant in the room? Biomed. Pharmocother., 2008, 62, 236-249.
16. Chiueh, C.C. Neuroprotective propertiws of nitric oxide. Ann. N.Y. Acad. Sci., 1999, 890, 301-311.
17. Bartsch, H.; Nair, J. Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res., 2005, 591, 34-44.
18. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T. D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Internat. J. Biochem. Cell Biol., 2007, 39, 44-84.
19. Nair, U.; Bartsch, H.; Nair, J. Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: Areview of published adduct types and levels in humans. Free Radic. Biol. Med., 2007, 43, 1109-1120.
20. Xu, J.; Ma, M.; Purcell, W. M. Characterisation of some cytotoxic endpoints using rat liver and Hepg2 spheroids as in vitro models and their application in hepatotoxicity studies: I. glucose metabolism and enzyme release as cytotoxic markers. Toxicol. Appl. Pharmacol., 2003a, 189, 100-111.
21. Xu, J.; Ma, M.; Purcell, W. M. Characterisation of some cytotoxic endpoints using rat liver and Hepg2 spheroids as in vitro models and their application in hepatotoxicity studies: II. spheroid cell spreading inhibition as a new cytotoxic marker. Toxicol. Appl. Pharmacol., 2003b, 189, 112-119.
22. Xu, J.; Purcell, M. W. Energy metabolism and transformation as endpoints to screen hepatotoxicity using a liver spheroid model. Toxicol. Appl. Pharmacol., 2006, 216, 293-302.
23. Howe, A. K. Regulation of actin-based cell migration by cAMP/PKA. Biochim. Biophys. Acta, 2004, 1692, 159-174.
24. Heussner, A.H.; O'Brien, E.; Dietrich, D.R. Effects of repeated ochratoxin exposure on renal cells in vitro. Toxicol. In Vitro, 2007, 21, 72-80.
25. Barthold, C. L.; 25 Schier J. G. Organic Phosphorus Compounds - Nerve Agents. Crit. Care Clin., 2005, 21, 673-689.
26. Kastanioudakis, J.; Skevas, A.; Assimakopoulos, D.; Anastasopoulos, D. Hearing loss and vestibular dysfunction in childhood from the use of streptomycin in Albania. Internat. J. Pediatr. Otorhinolaryngol., 1993, 26, 109-115.
27. Bass, A.; Kinter, L.; Williams P. Origine, practices and future of safety pharmacology. J. Pharmacol. Toxicol. Methods, 2004, 49, 145-151.
28. Welss, T., Basketter, D. A., Schroder K. R. (2003). In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol. In Vitro. 18, 231-243.
29. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13, 1859-1876.
30. Shao, Z-Y.; Zhai, B-J.; Zhao, C-L.; Hu, K.; Shen, D-M.; Wu, F. Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2). Ultrasonics, 2008, 48, 297-302.
31. Khatsenko, O.G.; Barteneva, N. S.; de la Maza, L. M.; Kikkawa, Y. Role of nitric oxide in the inhibition of cytochrome P450 in the liver of mice infected with Chlamydia trachomatis. Biochem. Pharmacol., 1998, 55, 1835-1842.
32. López-García, M. P. Endogenous nitric oxide is responsible for the early loss of P450 in cultured rat hepatocytes, FEBS Lett., 1998, 438, 145-149.
33. Nicholls-Grzemski, F. A.; Timenstein, M. A.; Fariss, M. W. Timedependent production of nitric oxide by rat hepatocyte suspensions. Biochem. Pharmacol., 1999, 57, 1223-1226.
34. Ma, M., Xu, J.; Purcell, W. M. Biochemical and functional changes of rat liver spheroids during spheroid formation and maintenance in culture: I. Morphological maturation and kinetic changes of energy metabolism, albumin synthesis and activities of some enzymes. J. Cell. Biochem., 2003, 90, 1166-1175.
35. Xu, J.; Ma, M.; Purcell, W. M. Biochemical and functional changes of rat liver spheroids during spheroid formation and maintenance in culture: II. Nitric oxide synthesis and related changes. J. Cell. Biochem., 2003c, 90, 1176-1185.
36. Liu, J.; Kuznetsova, L. A.; Edwards, G. O.; Xu, J.; Ma, M.; Purcell, W. M.; Jackson, S. K.; Coakley, W. T. Functional Three-Dimensional HepG2 Aggregate Cultures generated from an ultrasound trap: comparison with HepG2 spheroids. J. Cell. Biochem., 2007, 9999, 1-10.
37. Calabrese, E. J.; Baldwin L. A. Hormesis: U-shaped dose-responses and their centrality in toxicology. Trends Pharmacol. Sci., 2001, 22, 285-291.
38. Calabrese, E. J.; Baldwin L. A. Applications of hormesis in toxicology, risk assessment and chemotherapeutics. Trends Pharmacol. Sci., 2002, 23, 331-337.
39. Calabrese E. J. Hormesis: changing view of the dose-respones, a personal account of the history and current status. Mutat. Res., 2002, 511, 181-189.
40. Calabrese, E. J.; Baldwin L. A. Hormesis and high-risk groups. Regul. Toxicol. Pharmacol., 2002, 35, 414-428.
41. King, A.V.; Jones, P.A. In-house assessment of modified in vitro cytotoxicity assay for higher throuput estimation of acute toxicity. Toxicol. In Vitro, 2003, 17, 717-722.